Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

This study has been terminated.
(SBI Biotech who provided the drug for this study has decided to no longer support the study or GNKG168.)
Information provided by (Responsible Party):
Nobuko Hijiya, MD, Therapeutic Advances in Childhood Leukemia Consortium Identifier:
First received: November 28, 2012
Last updated: August 27, 2014
Last verified: August 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: March 2015
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)